| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
ZL006 is an efficient inhibitor of the nNOS/PSD-95 protein-protein interaction and showed great promise in cellular experiments and animal models of ischemic stroke and pain. In vitro, ZL006 does not interact with the PDZ domains of nNOS or PSD-95, nor inhibit the nNOS-PDZ/PSD-95-PDZ interface by interacting with the β-finger of nNOS-PDZ. ZL006 presents little cytotoxicity, and a growth inhibition of BCECs is not found at low concentration of 0.001, 0.01, 0.1, 1 and 10 μg/mL. ZL006 does not inhibit the nNOS-PDZ/PSD-95-PDZ interaction, or perturb the nNOS β-finger.
| ln Vitro |
ZL006 exhibits minimal cytotoxicity, and at low concentrations of 0.001, 0.01, 0.1, 1, and 10 μg/mL, there is no growth inhibition of BCECs. At a concentration of 10 μg/mL, T7-P-LPs/ZL006 exhibits significantly increased cytotoxicity. Following a 0.5-hour incubation period, ZL006 loads P-LPs and T7-P-LPs at concentrations ranging from 100 μg/mL to 600 μg/mL in BCECs[1]. ZL006 does not disrupt the nNOS β-finger or impede the nNOS-PDZ / PSD-95-PDZ interaction[2].
|
||
|---|---|---|---|
| ln Vivo |
Owing to its superior brain targeting delivery, T7-P-LPs/ZL006 shows a marked increase in drug accumulation in the brain tissue when compared to P-LPs/ZL006 and free ZL006. P-LPs/ZL006 show a notable reduction in drug build-up in the kidney and liver[1].
|
||
| Animal Protocol |
|
||
| References |
|
| Molecular Formula |
C14H11CL2NO4
|
|
|---|---|---|
| Molecular Weight |
328.15
|
|
| Exact Mass |
327.006
|
|
| Elemental Analysis |
C, 51.24; H, 3.38; Cl, 21.61; N, 4.27; O, 19.50
|
|
| CAS # |
1181226-02-7
|
|
| Related CAS # |
|
|
| PubChem CID |
44207238
|
|
| Appearance |
Light yellow to khaki solid powder
|
|
| Density |
1.6±0.1 g/cm3
|
|
| Boiling Point |
530.4±50.0 °C at 760 mmHg
|
|
| Flash Point |
274.6±30.1 °C
|
|
| Vapour Pressure |
0.0±1.5 mmHg at 25°C
|
|
| Index of Refraction |
1.728
|
|
| LogP |
4.57
|
|
| Hydrogen Bond Donor Count |
4
|
|
| Hydrogen Bond Acceptor Count |
5
|
|
| Rotatable Bond Count |
4
|
|
| Heavy Atom Count |
21
|
|
| Complexity |
371
|
|
| Defined Atom Stereocenter Count |
0
|
|
| SMILES |
ClC1=C([H])C(=C([H])C(=C1O[H])C([H])([H])N([H])C1C([H])=C([H])C(C(=O)O[H])=C(C=1[H])O[H])Cl
|
|
| InChi Key |
RTEYSQSXRFVKTJ-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C14H11Cl2NO4/c15-8-3-7(13(19)11(16)4-8)6-17-9-1-2-10(14(20)21)12(18)5-9/h1-5,17-19H,6H2,(H,20,21)
|
|
| Chemical Name |
4-[(3,5-dichloro-2-hydroxyphenyl)methylamino]-2-hydroxybenzoic acid
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.62 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.62 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.62 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0474 mL | 15.2369 mL | 30.4739 mL | |
| 5 mM | 0.6095 mL | 3.0474 mL | 6.0948 mL | |
| 10 mM | 0.3047 mL | 1.5237 mL | 3.0474 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
